Subject(s)
Antirheumatic Agents , Arthritis, Rheumatoid , Biological Products , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/epidemiology , Biological Factors , Biological Products/adverse effects , Comorbidity , HumansABSTRACT
Background and objective: There is absence of data on the prevalence of osteoporosis before corrective surgery of the lumbar spine. We do not know the impact of bone assessment before corrective spine surgery, regarding the prevalence of osteoporosis, risk factors for osteoporosis, and prescription of osteoporotic treatment. Our objective was to evaluate the impact of assessment of bone status before corrective surgery of the lumbar spine. Methods: This retrospective study was conducted over a period of 30 months. Patients included were over 50 years old and had been referred to rheumatology consultation prior to corrective surgery of the lumbar spine with osteosynthesis, for scoliosis or spondylolisthesis. Assessment of bone status consisted in looking for risk factors for osteoporotic fracture, performing bone densitometry with the calculation of TBS (trabecular bone score) and the possible introduction of treatment for osteoporosis. Data were collected on complications related to bone fragility during follow-up. Results: Twenty-eight patients with a median age of 71.2 years (55.5-84.8) were included; 89% were women. T score was <-2.5 in 14.3% (4/28) and -1 to -2.5 in 42.9% (12/28) on at least one of the three sites analyzed. Fifty percent of patients had a TBS <1.2, a history of more than four falls per year, a duration of more than 20 s in the Timed Up and Go Test, and/or sedation treatment. Vitamin-calcium supplementation and treatment for osteoporosis were prescribed in 71.4% and 17.8% of cases, respectively. During follow-up, 3 patients had one or more osteoporotic vertebral fractures and 4 patients had loosening of implanted devices. Conclusion: Despite a low prevalence of densitometric osteoporosis and therapeutic management, one in four patients had a bone complication, suggesting the superiority of TBS as an indicator of bone status.
ABSTRACT
Osteoporosis is characterized by low bone mineral density (BMD) and fragility fracture and affects over 200 million people worldwide. Bone quality describes the material properties that contribute to strength independently of BMD, and its quantitative analysis is a major priority in osteoporosis research. Tissue mineralization is a fundamental process requiring calcium and phosphate transporters. Here we identify impaired bone quality and strength in Slc20a2-/- mice lacking the phosphate transporter SLC20A2. Juveniles had abnormal endochondral and intramembranous ossification, decreased mineral accrual, and short stature. Adults exhibited only small reductions in bone mass and mineralization but a profound impairment of bone strength. Bone quality was severely impaired in Slc20a2-/- mice: yield load (-2.3 SD), maximum load (-1.7 SD), and stiffness (-2.7 SD) were all below values predicted from their bone mineral content as determined in a cohort of 320 wild-type controls. These studies identify Slc20a2 as a physiological regulator of tissue mineralization and highlight its critical role in the determination of bone quality and strength. © 2019 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
Subject(s)
Bone and Bones/physiology , Sodium-Phosphate Cotransporter Proteins, Type III/genetics , Animals , Animals, Newborn , Bone Development , Bone Resorption/physiopathology , Bone and Bones/diagnostic imaging , Calcification, Physiologic , Calcinosis/diagnostic imaging , Calcinosis/genetics , Cells, Cultured , Chondrocytes/metabolism , Humans , Incisor/ultrastructure , Mice, Inbred C57BL , Mice, Knockout , Osteoblasts/metabolism , Phenotype , Skull/diagnostic imaging , Sodium-Phosphate Cotransporter Proteins, Type III/deficiency , Tooth/growth & development , X-Ray MicrotomographyABSTRACT
Sonography of the shoulder is widely used to assess various disorders, including tendinous diseases of the rotator cuff and the long head of the biceps brachii muscle. The shoulder is commonly explored through anterior, superior, and posterior approaches, but the inferior axillary approach is rarely considered in the literature. However, this technique allows the direct visualization of relevant anatomic structures. The aim of this pictorial essay is, first, to technically describe this approach and the normal musculoskeletal sonographic anatomy of the region and, second, to present the sonographic findings of shoulder disorders that may be helpfully explored this technique.
Subject(s)
Axilla/diagnostic imaging , Joint Diseases/diagnostic imaging , Shoulder Joint/diagnostic imaging , Ultrasonography/methods , HumansSubject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal/therapeutic use , Crohn Disease/complications , Crohn Disease/drug therapy , Spondylarthritis/complications , Spondylarthritis/drug therapy , Adrenal Cortex Hormones/therapeutic use , Adult , Crohn Disease/diagnosis , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Infliximab/therapeutic use , Spondylarthritis/diagnosis , Sulfasalazine/therapeutic use , Treatment OutcomeSubject(s)
Arthritis, Rheumatoid/epidemiology , Disease Progression , Smoking/adverse effects , Smoking/epidemiology , Adult , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/diagnostic imaging , Arthritis, Rheumatoid/drug therapy , Female , Humans , Male , Middle Aged , Prognosis , Radiography/methods , Risk Assessment , Severity of Illness Index , Smoking Cessation , Treatment OutcomeABSTRACT
OBJECTIVES: The aim of this study was to investigate the clinical value of sVE and anti-vascular endothelial-cadherin antibodies (AAVE) in RA treated with etanercept or adalimumab combined with methotrexate. METHODS: This was an 18-month prospective multicenter study in which patients had active RA, requiring TNF antagonist. sVE rates and AAVE titers were measured respectively by dot blot and ELISA. The relationship of these biomarkers with parameters reflecting articular or systemic disease activity, progression of structural damage, and response or remission to treatment was analyzed. RESULTS: Forty-eight patients received TNF blocking agents. Variation of sVE rates were significantly correlated with that of C-reactive protein (CRP) levels at weeks 6, 12, 26 and 52. A significant decrease in sVE levels was observed in the group of patients exhibiting a decrease in CRP levels as compared to the patient group with unmodified CRP. AAVE at baseline were correlated with rheumatoid factor. Kinetics analysis of sVE levels and AAVE titers showed that their level were not associated with disease activity score and to methotrexate/adalimumab or etanercept response. CONCLUSIONS: sVE is a biomarker associated with systemic RA activity under anti-TNF. AAVE are related to autoantibodies usually associated to RA.
Subject(s)
Adalimumab/therapeutic use , Antigens, CD/analysis , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/immunology , Autoantibodies/analysis , Cadherins/analysis , Etanercept/therapeutic use , Adult , Aged , Antigens, CD/immunology , Arthritis, Rheumatoid/diagnosis , Autoantibodies/immunology , Biomarkers/analysis , Cadherins/immunology , Cohort Studies , Female , Follow-Up Studies , France , Humans , Longitudinal Studies , Male , Middle Aged , Prospective Studies , Risk Assessment , Severity of Illness Index , Solubility , Treatment OutcomeABSTRACT
INTRODUCTION: Shrinking lung syndrome (SLS) is a rare respiratory manifestation of systemic lupus erythematosus (SLE), characterized by dyspnea, chest pain, elevated hemidiaphragm and a restrictive pattern on pulmonary function tests. Here, we report 15 new observations of SLS during SLE and provide a systematic literature review. We studied the clinical, biological, functional and morphologic characteristics, the treatments used and their efficacy. METHODS: The inclusion criteria were all patients with SLE defined by the American College of Rheumatology criteria Hochberg (1997) , associated with a restrictive pattern on pulmonary function tests. The exclusion criteria were all differential diagnoses of restrictive patterns, including obesity and pulmonary fibrosis. The patients were recruited from local databases through chest physicians, rheumatologists and internists. The data for the literature review were extracted from the Medline database using "shrinking lung syndrome" and "lupus" as key words. RESULTS: All 15 new cases were women with a median age at SLS onset of 27years old (range 17-67years). All of them complained of dyspnea and all but one of chest pain. The antibodies were similar to those found in SLE, although the anti-SS-A was positive in 10 of 13 cases. Thoracic imaging showed elevated hemidiaphragm (12/15) and/or basal atelectasia (8/15). All of the patients had an isolated restrictive pattern on PFT, with a median decrease >50% of lung volume. All of the patients were treated, using corticosteroids (11/15), immunosuppressive drugs (8/15), beta-mimetics (2/15), physiotherapy (3/15) and/or colchicine (1/15). Improvement was described in 9 of 12 patients and stability in 3 of 12. We extracted 155 cases of SLE-associated SLS from the Medline database. The clinical, biological and functional parameters were similar to our cases. Clinical improvement was described in 48 of 52 cases (94%) and PFT improvement in 36 of 47 cases. Worsening occurred in 4 cases. CONCLUSION: SLS is a rare SLE manifestation. Pain and parietal inflammation seem to play important pathogenic roles. Steroids and antalgics are the most commonly used therapies with good responses. There is no proof of efficacy with immunosuppressive drugs for this entity. Rituximab can be discussed after failure of corticosteroids, as well as antalgics, theophylline and beta-mimetics.
Subject(s)
Immunosuppressive Agents/therapeutic use , Lung Diseases/etiology , Lupus Erythematosus, Systemic/complications , Adolescent , Adult , Aged , Female , Humans , Lung Diseases/drug therapy , Lung Diseases/immunology , Lupus Erythematosus, Systemic/drug therapy , Middle Aged , Multicenter Studies as Topic , Retrospective Studies , Syndrome , Treatment Outcome , Young AdultSubject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Atlanto-Occipital Joint/diagnostic imaging , Sacroiliac Joint/diagnostic imaging , Spondylarthritis/diagnostic imaging , Spondylarthritis/drug therapy , Adult , Atlanto-Occipital Joint/pathology , Disease Progression , Follow-Up Studies , Humans , Magnetic Resonance Imaging/methods , Male , Neck Pain/diagnosis , Neck Pain/etiology , Pain Measurement , Sacroiliac Joint/pathology , Spondylarthritis/physiopathology , Tomography, X-Ray Computed/methods , Treatment OutcomeABSTRACT
We report the occurrence of Sweet's syndrome in a patient treated with adalimumab for Crohn's disease. The imputability of adalimumab is at issue.
Subject(s)
Adalimumab/adverse effects , Crohn Disease/complications , Crohn Disease/drug therapy , Sweet Syndrome/diagnosis , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Corticosterone/therapeutic use , Female , Humans , Recurrence , Sweet Syndrome/drug therapyABSTRACT
A 47-year-old woman with rheumatoid arthritis (RA) treated successively with infliximab, abatacept, and etanercept spontaneously developed subcutaneous bruises and a noncompressive hematoma 11 months after starting etanercept therapy (50mg/week). Her prothrombin time was normal but her activated partial thromboplastin time was increased to 2.48 (normal range, 0.85-1.17). She had a circulating anticoagulant (Rosner index, 45; normal,<13) due to an anti-factor VIII antibody in a titer of 45 Bethesda units. Her factor VIII level was less than 1% (normal range, 55-150). The etanercept and leflunomide were stopped and prednisone was given in a daily dosage of 1mg/kg, in combination with rituximab, two 1-g doses at an interval of 2 weeks. After 5 months, persistence of the anti-factor VIII antibody prompted the initiation of azathioprine therapy, 2mg/kg/d. A remission was achieved 9 months after the diagnosis of acquired hemophilia and was sustained at last follow-up after 3 years. This new case of acquired hemophilia in a patient with RA may reflect a simple association or an inducing role of etanercept.
Subject(s)
Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Etanercept/adverse effects , Hemophilia A/chemically induced , Antirheumatic Agents/therapeutic use , Etanercept/therapeutic use , Female , Humans , Middle AgedSubject(s)
Gout Suppressants/therapeutic use , Gout/drug therapy , Hyperuricemia/drug therapy , Xanthine Oxidase/antagonists & inhibitors , Aged , Allopurinol/therapeutic use , Febuxostat , Female , Gout/blood , Guideline Adherence , Hospitalization , Humans , Male , Prevalence , Thiazoles/therapeutic useABSTRACT
OBJECTIVE: The use of anti-tumor necrosis factor (TNF) agents to treat joint manifestations of sarcoidosis has not been described. We evaluated the efficacy and safety of three such biologics in patients with these symptoms refractory to conventional therapy (nonsteroidal anti-inflammatory drugs, corticosteroids, and/or disease-modifying antirheumatic drugs). METHODS: This retrospective study, covering January 2001 to September 2011, examined clinical-biological parameters collected before anti-TNF treatment (age, sex, duration of disease evolution, drugs taken), and at introduction and under anti-TNF therapy (number of painful and swollen joints, visual analog scale score of global disease activity, disease-activity score of 28 joints with erythrocyte sedimentation rate or C-reactive protein, TNF-antagonist duration). At 3, 6, and 12 months, anti-TNF impact on joints and the therapeutic response according to European League Against Rheumatism criteria used for rheumatoid arthritis were assessed. RESULTS: Ten patients' data were evaluated; some of them had received several anti-TNF agents (median [range] duration on each biotherapy was 10 [4-30] months), which enabled analysis of 19 prescriptions. The total duration of anti-TNF exposure was 17.6 patient-years, which was started a median of 3 (0.33-17) years after sarcoidosis diagnosis. The median numbers of painful and swollen joints were 1 (0-28) and 0 (0-9), respectively. Despite rapid efficacy, after 1 year of treatment, clinical (especially joint) and biological parameters were comparable to pretreatment, and only the corticosteroid dose was significantly lower (P=0.03). One case of mild skin toxicity was noted. CONCLUSION: TNF antagonists allowed significant steroid sparing and were well tolerated, but do not seem to be effective against sarcoidosis joint involvement.
ABSTRACT
Macrophage activation syndrome (MAS) is a rare and serious complication of adult-onset Still's disease. We describe a case in a 49-year-old woman with Still's disease refractory to glucocorticoids, methotrexate, and infliximab. Anakinra provided satisfactory disease control for 1 year, after which escape phenomenon occurred. After four tocilizumab injections, cutaneous melanoma developed. The persistent systemic manifestations prompted treatment with two canakinumab injections. Ten days later, she had a spiking fever, dyspnea, low back pain, abdominal pain, odynophagia, and hepatomegaly. Laboratory tests showed liver cytolysis (180 IU/L; N: 10-35), acute renal failure (creatinine, 407 µmol/L; N:50-100), thrombocytopenia (60 G/L; N: 150-400), leukocytosis (12,200/mm(3); N: 4000-10,000), hypertriglyceridemia (5070 mmol/L; N: 0.4-1.6), lactate dehydrogenase elevation (4824 IU/L; N: 135-250), and hyperferritinemia (97 761 µg/L; N:15-150). Examination of a bone marrow biopsy showed phagocytosis. Tests were negative for viruses and other infectious agents. Glucocorticoid therapy (1.5 mg/Kg/d) and intravenous polyvalent immunoglobulins (0.5 g/Kg/d) were given. Her condition improved despite the many factors of adverse prognostic significance (thrombocytopenia, absence of lymphadenopathy, and glucocorticoid therapy at diagnosis). This is the first reported case of MAS after canakinumab therapy in a patient with adult-onset Still's disease.